| Document Date: 2014-11-03 11:26:17
Open Document File Size: 28,99 KBShare Result on Facebook
City Osaka / London / / Company Shionogi Inc. / ViiV / ABC / Shionogi & Co. Ltd. / Shionogi-ViiV Healthcare LLC / Healthcare ViiV Healthcare / Pfizer / GlaxoSmithKline / HIV/AIDS / Japan Shionogi & Co. / ViiV Healthcare / / Country United Kingdom / / Event FDA Phase / / IndustryTerm HIV Therapy / pharmaceutical / healthcare / in-line products / pharmaceuticals / treatment of HIV / other HIV treatment / with respect to product / / MedicalCondition allergic reaction / HIV / headache / HBV / stomach pain / very low blood pressure / Nausea / heart disease / hepatitis C / severe hypersensitivity / HIV1 infection / hypersensitivity / diarrhea / hepatitis / tiredness / liver disease / infections / serious allergic reaction / HIV infection / pneumonia / cancer / extreme tiredness / Shortness of breath / herpes virus / diabetes / fever / allergy / Metabolic Syndrome / high cholesterol / vomiting / heart attack / diseases / both hepatitis B / AIDS / Infectious Diseases / infection / high blood pressure / dizziness / cough / depression / Rash / tuberculosis / / MedicalTreatment antiretroviral therapy / / Organization Federal Trade Commission / / Person Dominique Limet / Sapan Shah / Sally Ferguson Gary Davies / Rebecca Hunt Claire Brough / Marc Meachem / / / Position Chief Executive Officer / pharmacist / Analyst / Private / President & CEO / / Product efavirenz / zidovudine / TRIZIVIR / abacavir sulfate / ZIAGEN / Epzicom / ribavirin / abacavir / lamivudine / FDC tablet / GSK1265744 / / URL www.shionogi.co.jp / www.epzicom.com / www.shionogiinc.com / www.viivhealthcare.com / www.treathiv.com / /
SocialTag |
Shionogi-ViiV Healthcare Starts Phase III Trial for “572-Trii” Fixed-Dose Combination HIV Therapy London, UK, 3 February 2011 – Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the c